Market Research Report
Cachexia - Pipeline Review, H2 2017
|Published by||Global Markets Direct||Product code||192512|
|Published||Content info||42 Pages
Delivery time: 1-2 business days
|Cachexia - Pipeline Review, H2 2017|
|Published: September 12, 2017||Content info: 42 Pages||
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cachexia - Pipeline Review, H2 2017, provides an overview of the Cachexia (Musculoskeletal Disorders) pipeline landscape.
Cachexia is the dramatic weight loss and muscle atrophy seen in patients with chronic illness including type I diabetes, multiple sclerosis, HIV, cancer, and in individuals with age-associated "failure to thrive" syndrome. Symptoms include involuntary (unintentional) weight loss, skeletal muscle wasting, anorexia/loss of appetite, lowered quality of life. Treatment includes diet, nutritional supplements, exercise and medications.
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Cachexia - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Cachexia (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Cachexia (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Cachexia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 1, 5, 3 and 1 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.
Cachexia (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.